COMMUNIQUÉS West-GlobeNewswire

Biosplice Announces First Patient Dosed in Phase 2 Trial of Cirtuvivint for Advanced Soft-Tissue Sarcomas

01/05/2025 - 12:00

Multicenter study sponsored by SELNET to evaluate cirtuvivint as a second-line monotherapy in selected sarcoma subtypes SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical- [...]

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

01/05/2025 - 12:01

4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026 Additional analyses of mavorixafor clinical trial data increase confidence in successful [...]

Coloplast A/S Revised guidance for FY 2024/25

01/05/2025 - 12:23

Coloplast revises financial guidance for FY 2024/25 and pre-announces H1 2024/25 key financial figures Coloplast revises the guidance on organic growth and EBIT margin before special items for FY 2024/25. The organic [...]

Teleflex Reports First Quarter Financial Results and Full Year 2025 Outlook

01/05/2025 - 12:30

WAYNE, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 30, 2025. First quarter financial summary Revenues of $ [...]

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

01/05/2025 - 12:30

– U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND ® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with [...]

FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain

01/05/2025 - 13:00

LONDON and NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an [...]

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025

01/05/2025 - 13:00

Panel to Discuss Current Challenges Encountered by Patients with HCV , Results from Atea’s Phase 2 Study of the Regimen of Bemnifosbuvir and Ruzasvir, and What a New Optimized HCV Therapy Could Provide for Prescribers [...]

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025

01/05/2025 - 13:00

― Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ― ― On track to provide clinical data from the 12 mg dose [...]

Sol-Gel Announces Reverse Share Split

01/05/2025 - 13:00

NESS ZIONA, Israel, May 01, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the “Company”) (NASDAQ: SLGL), a clinical-stage dermatology company, today announced a reverse share split (the “Reverse Split”) of the [...]

Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates

01/05/2025 - 13:00

First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as [...]

Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET

01/05/2025 - 13:00

WARREN, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]

Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

01/05/2025 - 13:00

BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. [...]

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

01/05/2025 - 13:00

NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is [...]

Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

01/05/2025 - 13:00

Data suggest BP1001-A prevents fatty acid-induced insulin resistance in cells HOUSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize [...]

Microbix Presenting at the 2025 Bloom Burton Conference

01/05/2025 - 13:00

MISSISSAUGA, Ontario, May 01, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix ® ), a life sciences innovator, manufacturer, and exporter, announces it will be attending and [...]

BioStem to Showcase its Leading BioREtain® Technology at the Symposium for Advanced Wound Care (SAWC) Spring Meeting

01/05/2025 - 13:00

Company to co-exhibit with strategic partner Venture Medical, LLC, highlighting collaborative innovation in chronic wound care management Three accepted scientific posters will feature BioStem’s advanced allograft [...]

Ligand to Participate in May Investor Conferences

01/05/2025 - 13:00

JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: H.C. [...]

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

01/05/2025 - 13:00

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting [...]

Roquette finalise l’acquisition d’IFF Pharma Solutions

01/05/2025 - 08:00

Roquette finalise l’acquisition d’IFF Pharma Solutions Lille, le 1 mai 2025 – Roquette, un leader mondial des ingrédients d'origine végétale et des excipients pharmaceutiques destinés aux secteurs de la santé et de la [...]